Skip to main content

Roche's 2009 MDx Sales Rise 2 Percent; Applied Science Sales up 12 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today reported that full-year 2009 sales of its molecular diagnostic products rose 2 percent to CHF 1.18 billion ($1.11 billion).

The Swiss drugs, diagnostics, and life science research products firm said that its molecular diagnostics' core blood screening and virology segments "delivered a solid single-digit rise in overall sales."

Roche's Applied Science business, which includes its life science tools such as 454 Life Sciences' sequencing instruments, are part of the firm's Diagnostics Division and had 12 percent revenue growth year over year to CHF 870 million ($820.9 million).

Roche said that the Applied Science unit saw "strong demand for the MagNA Pure and LightCycler product lines, [which] fuelled further above-market growth.

The Diagnostics Division, which also includes Professional Diagnostics, and Diabetes Care, among other segments, brought in total 2009 revenues of CHF 10.10 billion ($9.53 billion), up 4 percent from 2008.

Overall, the Roche Group had 8 percent revenue growth to CHF 49.10 billion ($46.35 billion), boosted by 8 percent growth in its Pharmaceuticals Division. Its full-year net profit dropped, however, 22 percent to CHF 8.51 billion ($8.06 billion), due primarily to costs associated with its takeover of Genentech.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.